Exelixis Inc
EXEL - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$17.44B
Close$
$178.80
145.8% upside
Current Fair Value
145.8% upsideUndervalued by 145.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $17.44 Billion |
|---|---|
| Enterprise Value | $17.33 Billion |
| Earnings per Share | $2.88 |
| Beta | 0.42 |
| Outstanding Shares | 246,756,000 |
Return
| Return on Equity | 34.74% |
|---|---|
| Return on Assets | 25.68% |
| Return on Invested Capital | 36.69% |
Valuation & Multiples
| P/E Ratio | 20.11 |
|---|---|
| PEG | 158.81 |
| Price to Sales | 10.39 |
| Price to Book Ratio | 10.39 |
| Enterprise Value to Revenue | 9.13 |
| Enterprise Value to EBIT | 22.14 |
| Enterprise Value to Net Income | 27 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 3, 2026
EPS Estimate
$0.88
Consensus analyst estimateRevenue Estimate
$646.95 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 81.84% |
|---|---|
| Total Calls | 3,000▼ 99.67% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.38%▼ 98.83% |
|---|---|
| Total Invested | $785.51M▼ 94.48% |
| Investors Holding | 252▼ 529.00% |
About Exelixis Inc
1,077 employees
CEO: Michael Morrissey
Exelixis, Inc. is a biotechnology firm primarily focused on addressing oncology, dedicated to the discovery, development, and commercialization of innovative therapeutic agents for cancer treatment within the United States. The company m...